VentriPoint Diagnostics Ltd.

UniDoc Health and Ventripoint Diagnostics Sign MOU to Evaluate Scalable Remote Cardiac Assessment and Screening Platform

2026-08-05 08:30:00

Proposed collaboration would combine UniDoc Health Cubes and connected-care infrastructure with Ventripoint's AI-enabled VMS+™ platform in a hub-and-spoke care model   Toronto, Ontario – TheNewswire – August 5, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT; OTC:VPTDF) a leader in AI-powered cardiac imaging, is pleased to announce that it has signed a memorandum of understanding ("MOU") with UniDoc Health Corp. ("UniDoc") to evaluate a potential collaboration focused on remote cardiac assessment and cardiovascular screening.

Ventripoint Strengthens Board with Appointment of MedTech Executive and Commercialization Leader Dr. Philip Toleikis

2026-07-29 16:55:00

Toronto, Ontario – July 29, 2026 – TheNewswire - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV: VPT; OTC: VPTDF), a leader in AI-powered cardiac imaging, today announced the appointment of Dr. Philip M. Toleikis to its Board of Directors, adding extensive public company leadership, capital markets expertise, and medical technology commercialization experience as the Company accelerates the global expansion of its VMS+ cardiac imaging platform.   Dr. Toleikis is a seasoned life sciences executive with a proven track record of building innovative healthcare companies, securing capital, developing strategic partnerships, and creating shareholder value. His appointment further strengthens Ventripoint's governance as the Company advances commercial execution and positions itself for growth.

Ventripoint Issue Shares for Payment of Debenture Interest

2026-07-22 16:30:00

Toronto, Ontario – TheNewswire - July 22, 2026 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT) announces it will satisfy debenture interest payment obligations with the issuance of common shares, subject to TSX Venture Exchange (“ TSXV ”) approval. The Corporation will issue an aggregate of 601,115 common shares (“ Shares ”) for the payment of an aggregate of $72,143  of interest owing on certain outstanding Convertible Debentures issued by the Corporation on May 10, 2024, June 28, 2024 and December 16, 2024 . The Convertible Debentures bear interest at the rate of 10% per annum, payable every 6 months. The Shares will be issued at a deemed price of ($0.12), subject to the approval of TSXV, and are subject to a hold period of 4 months and one day. The issuance of the Shares will not create a control person of the Corporation.   About Ventripoint Diagnostics Ltd.

Ventripoint Engages More Capital Ltd.

2026-07-22 08:05:00

Pioneering Medical AI Company Moves to Increase Awareness of VMS+ System and Proprietary Knowledge Based Reconstruction Technology   Toronto, Ontario – TheNewswire – July 22, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, is pleased to announce that it has engaged More Capital Ltd. ("More Capital"), a Toronto, Ontario-based private investment and strategic advisory firm, under a strategic growth and advisory agreement focused on commercial partnerships, market expansion and broader awareness of the Company's technology, subject to acceptance by the TSX Venture Exchange ("TSX-V").

Ventripoint Diagnostics' VMS+ Technology Selected for World-First AI Cardiac Monitoring Study in Breast Cancer Patients

2026-07-20 10:50:00

Ventripoint's VMS+ platform to be evaluated alongside a second AI technology in a landmark NHS study exploring earlier detection of chemotherapy-related heart damage   Toronto, Ontario – TheNewswire – July 20, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in the application of artificial intelligence to echocardiography, today announced that its VMS+ technology has been selected for use in AIRES (Artificial Intelligence Reconstruction of Echocardiography Study), a newly launched clinical research study at The Royal Wolverhampton NHS Trust (RWT) in the United Kingdom.

Ventripoint and Ollie Hinkle Heart Foundation Partner to Expand Access to AI-Powered Heart Imaging for Children Living with Heart Disease

2026-06-26 08:10:00

Collaboration inspired by families' lived experiences aims to reduce barriers to advanced cardiac imaging and ensure no parent faces impossible decisions when seeking answers about their child's heart.     Toronto, Ontario – TheNewswire – June 26, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced a strategic collaboration with Ollie Hinkle Heart Foundation (OHHF) to expand access to AI-powered cardiac imaging and clinical decision-support technology for children and adults living with congenital and childhood-onset heart disease.

Ventripoint Diagnostics Announces Support for the Global Congenital Heart Disease Alliance

2026-06-15 08:10:00

Toronto, Ontario – TheNewswire – June 15, 2026 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a pioneer in advanced cardiac imaging, today announced its support for the Global Congenital Heart Disease Alliance (“GCHDA”), a newly forming industry alliance dedicated to accelerating the development, commercialization, and global adoption of congenital cardiovascular technologies.   GCHDA brings together industry partners, clinicians, researchers, regulators, investors, and patient communities to address the unique challenges facing innovators in congenital heart disease (CHD) - the most common birth defect in the world. Through membership and advocacy programs, multi-center research collaboration, and a convening platform of summits and innovation showcases, GCHDA aims to build a unified support ecosystem for a field that has long been fragmented.

Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript

2026-06-03 02:42:00

Ventripoint Diagnostics Ltd. (VPT:CA) Shareholder/Analyst Call Transcript